Date Release

December 12

FDA Accepts Takeda and Lundbeck’s Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
December 3 Three-Year Data From Sabril®(vigabatrin) Registry Presented at American Epilepsy Society Annual Meeting
December 3 Results of Long-Term, Open-Label Extension Study Evaluating ONFI® (clobazam) CIV Presented at American Epilepsy Society Annual Meeting 
November 30 Art Display Created by People with Epilepsy Highlights Benefits of Complementary Therapy
November 14 Thousands Join Lundbeck and the Hereditary Disease Foundation to Build Hope for Huntington’s Disease
November 8 Takeda and Lundbeck Launch New Major Depressive Disorder Online Resource for Physicians
October 1 Takeda and Lundbeck Announce the U.S. Submission of a New Drug Application for Vortioxetine, an Investigational Drug for the Treatment of Major Depressive Disorder
August 16 Join Lundbeck and the Hereditary Disease Foundation to Build Hope for Huntington’s Disease
June 8 Lundbeck Encourages Epilepsy Community to Attend Upcoming Partners Against Mortality in Epilepsy (PAME) Conference
May 21 Lundbeck and CHDI Foundation announce research collaboration to investigate candidate therapy for Huntington’s disease
May 8 Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
May 7 Results from a Phase 3 Study of Once-Monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting
April 23 Lundbeck Launches Website to Inspire and Engage the Epilepsy Community
April 13 New Book Features Stories from People Impacted by Challenging Types of Epilepsy
April 2 Mebaral® (mephobarbital tablets, USP) Product Discontinuation Information
February 2 Raise Your Hand to Support People with Rare Diseases
January 10 Build Hope for HD Fundraising Campaign Succeeds in Keeping Important Clinic Open
January 3 ONFI™ (clobazam) Tablets Now Available in the U.S. at Retail Pharmacies

Contact Us


Ashleigh Duchene
Associate Director, Public Relations
Email: ADUC@lundbeck.com
Phone: 312-802-2906


Rachel Vann
Senior Manager, Public Relations
Email: RVAN@lundbeck.com
Phone: 224-507-8401

Follow Us on Twitter!

Get our latest company news.

Click here
You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit. Click OK to continue or Cancel to return to Lundbeck.